Last reviewed · How we verify
NCT07414381
An Exploratory Study of Chenghuang Circadian Rhythm Regulator in Subjects With Sleep Disorders
NA trial testing Chenghuang Circadian Rhythm Regulator in Sleep Disorders in 15 participants. Completed in 2 September 2025.
18 July 2025
Quick facts
| Lead sponsor | Shanghai Cell Therapy Group Co.,Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 15 |
| Start date | 6 June 2025 |
| Primary completion | 18 July 2025 |
| Estimated completion | 2 September 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chenghuang Circadian Rhythm Regulator
Conditions studied
- Sleep Disorders — all drugs for Sleep Disorders →
Sponsor
Shanghai Cell Therapy Group Co.,Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Sleep Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, open-label, self-controlled clinical study to evaluate the sleep and immunity improvement of Chenghuang Circadian Rhythm Regulator in adult subjects with sleep disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07414381
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sleep Disorders
Currently open trials in the same condition.
- NCT00819208 — Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk · NA · active not recruiting
Other Shanghai Cell Therapy Group Co.,Ltd trials
Trials by the same sponsor.
- NCT07479667 — An Antibody-armored Dendritic Cell in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting
- NCT06732232 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06446128 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) · EARLY_PHASE1 · recruiting
- NCT06327997 — An Exploratory Study by Fast CAR T Cells · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07414381 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Cell Therapy Group Co.,Ltd
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07414381.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing